Alexion Pharmaceuticals

Press Releases

Wednesday, December 28, 2011

Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
Monday, December 12, 2011

New Data Confirm Hemolysis as Predictor of Thromboembolism and Early Death in Patients with PNH and Demonstrate Need To Test High-Risk Patients for PNH
Tuesday, November 29, 2011

Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Wednesday, November 23, 2011

Alexion to Present at the 23rd Annual Piper Jaffray Health Care Conference
Thursday, November 10, 2011

Longer-Term Data on Soliris Showed Significant and Sustained Benefits for Patients with aHUS
Monday, November 7, 2011

Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting
Thursday, October 20, 2011

Alexion Reports Third Quarter 2011 Results
Thursday, October 6, 2011

Alexion Pharmaceuticals to Report Third Quarter 2011 Results on Thursday, October 20, 2011
Friday, September 23, 2011

Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Friday, September 23, 2011

Alexion Receives CHMP Positive Opinion for Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European Union
Wednesday, September 14, 2011

Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting
Wednesday, September 14, 2011

Alexion to Present at the UBS Global Life Sciences Conference
Tuesday, September 6, 2011

Alexion to Present at the Morgan Stanley Global Healthcare Conference
Wednesday, August 31, 2011

Alexion to Present at the Stifel Nicolaus Healthcare Conference 2011
Tuesday, July 26, 2011

Alexion Pharmaceuticals Partners with the Connecticut Community Foundation to Award Scholarships to Eight Waterbury, Connecticut Public High School Graduates
Thursday, July 21, 2011

Alexion Reports Second Quarter 2011 Results
Thursday, July 7, 2011

Alexion Pharmaceuticals to Report Second Quarter 2011 Results on Thursday, July 21, 2011
Monday, June 20, 2011

Alexion Initiates Clinical Trial of Eculizumab as a Potential Treatment for Patients with STEC-HUS in Expanded Response to EHEC Crisis in Germany
Wednesday, June 15, 2011

Alexion to Present at the Wells Fargo Securities Healthcare Conference
Saturday, June 11, 2011

Researchers Present Final Data from Phase 2 Studies of Soliris® (eculizumab) in Patients with aHUS
Saturday, June 11, 2011

New Data Show Renal Impairment Is Strong Predictor of Early Death in Patients with PNH
Tuesday, June 7, 2011

Alexion to Present at the 31st Annual William Blair & Company Growth Stock Conference
Wednesday, June 1, 2011

FDA Grants Priority Review for Alexion's sBLA for Soliris® (eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Tuesday, May 31, 2011

Alexion to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
Monday, May 23, 2011

Researchers to Present Nine Studies on Soliris® (eculizumab) in Patients with PNH and aHUS at EHA Congress
Thursday, May 12, 2011

Alexion Shareholders Approve Increase in Authorized Shares for Previously Announced Stock Split
Thursday, May 5, 2011

Alexion to Present at Bank of America Merrill Lynch 2011 Health Care Conference
Tuesday, April 26, 2011

Alexion to Present at Deutsche Bank Securities 36th Annual Health Care Conference
Thursday, April 21, 2011

Alexion Reports First Quarter 2011 Results
Friday, April 8, 2011

Alexion Pharmaceuticals to Report First Quarter 2011 Results on Thursday, April 21, 2011
Thursday, April 7, 2011

Alexion Submits Applications for Soliris® (Eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the United States and European Union
Wednesday, March 30, 2011

Alexion Announces Two-For-One Stock Split
Tuesday, March 29, 2011

Alexion to Present at the 10th Annual Needham Healthcare Conference
Tuesday, March 1, 2011

Alexion to Present at the Cowen and Company 31st Annual Health Care Conference
Monday, February 28, 2011

Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2011
Tuesday, February 22, 2011

Alexion to Present at the Citi 2011 Global Health Care Conference
Thursday, February 10, 2011

Alexion Reports Fourth Quarter and Full Year 2010 Results
Thursday, February 10, 2011

Alexion Acquires Investigational Therapy for Infants Suffering From Catastrophic, Ultra-Rare Genetic Neurologic Disorder
Monday, January 31, 2011

Alexion Acquires Taligen Therapeutics and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio
Thursday, January 27, 2011

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2010 Results on Thursday, February 10, 2011
Tuesday, January 4, 2011

Alexion to Present at the 29th Annual JP Morgan Healthcare Conference